Eledon Pharmaceuticals Inc Stock Price, News & Analysis

Eledon Pharmaceuticals (NASDAQ: ELDN) has received a No Objection Letter from Health Canada for its clinical trial application of AT-1501, intended to replace tacrolimus in kidney transplant patients. This multicenter, open-label study will involve 6 to 12 subjects to assess AT-1501’s safety, efficacy, and pharmacokinetics. Interim data is expected in late 2022. According to CEO David-Alexandre Gros, this study aims to potentially improve transplant outcomes and decrease side effects associated with current immunosuppressive therapies.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced the appointment of Dr. Jan Hillson to its Board of Directors. Dr. Hillson is the Senior VP of Clinical Development at Alpine Immune Sciences and brings extensive experience in immunology and rheumatology. CEO David-Alexandre Gros expressed confidence that her insights will be valuable in advancing Eledon's lead drug, AT-1501, through clinical development. AT-1501 is designed to treat autoimmune diseases, organ transplants, and ALS. The company is focused on targeting the CD40L pathway for therapeutic benefits.

Eledon Pharmaceuticals (NASDAQ: ELDN), a clinical-stage biopharmaceutical company, announced a corporate presentation at the Ladenburg Thalmann Healthcare Conference on July 13 at 2:00 pm EST. The company focuses on developing treatments targeting autoimmune diseases, organ transplant requirements, and ALS. Its lead compound, AT-1501, is an anti-CD40L antibody designed to enhance efficacy and safety by inhibiting CD40L, thus regulating immune responses. A replay of the presentation will be available for 30 days post-event on the company’s website.

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), a biopharmaceutical firm focused on autoimmune diseases and organ transplant treatments, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:30pm EST. Interested participants can register here.

A replay will be available for 30 days on the company’s website. Eledon is developing AT-1501, an anti-CD40L antibody, for autoimmune diseases and transplants, aiming for improved safety and efficacy.

Eledon Pharmaceuticals reported its Q1 2021 financial results, highlighting continued enrollment in the Phase 2 trial of AT-1501 for ALS, with top line data expected in H1 2022. The company appointed four key executives, enhancing its leadership team. Q1 net loss was $8.5 million, or $0.57 per share, up from $8.2 million, or $8.52 per share, year-over-year. R&D expenses surged to $5.6 million, compared to $1.6 million in 2020. Eledon has $108.6 million in cash, ensuring operational funding into 2023. Upcoming milestones include initiating additional trials and presenting data at the American Society of Transplantation conference.

Eledon Pharmaceuticals, a clinical-stage biopharmaceutical company, announced presentations for its lead product candidate, AT-1501, at the American Transplant Congress (ATC) from June 4-9, 2021. The presentations include Phase 1 data on AT-1501's safety, tolerability, and pharmacokinetics, alongside pre-clinical data demonstrating its effectiveness in preventing islet allograft rejection in nonhuman primates. Two additional posters will cover pharmacokinetics, toxicity, and characterization of AT-1501. More information is available on the ATC website.

Eledon Pharmaceuticals (NASDAQ: ELDN) plans to announce its financial results for Q1 2021 on May 13, 2021, after trading closes. The management will conduct a conference call and webcast at 4:30 PM ET to discuss these results. The company focuses on developing therapies for autoimmune diseases and ALS, with its lead compound AT-1501 targeting the CD40L pathway. This innovative approach aims to improve safety and efficacy in treatments. A recording of the event will be available on Eledon's website for one year.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced a new development strategy for AT-1501 in renal transplantation as requested by the FDA. The agency has asked for specific non-human primate data before starting a Phase 2 trial in the U.S. Consequently, Eledon will conduct evaluations in primate models, expected to be completed by late 2022. Despite this shift, other development programs continue as planned, and no safety concerns regarding AT-1501 have been reported. The CEO emphasized the potential of AT-1501 as a treatment option for renal transplant patients.

Eledon Pharmaceuticals has announced the appointments of David Hovland, Ph.D. as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer. Dr. Hovland brings over 20 years of R&D experience, previously serving at Urovant Sciences and Allergan, while Mr. Smith has a successful track record at Urovant and Allergan. Their expertise is expected to advance the development of AT-1501, a novel antibody targeting the CD40 ligand. The company will issue stock options as inducement grants for their roles.